

DEC - 1 2011

K112979
P2/3

510(K) SUMMARY

510(K) SUMMARY

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

APPLICANT Asahi Intecc Co., Ltd.
1703 Wakita-cho, Moriyama-ku
Nagoya, Aichi 463-0024
Japan

OFFICIAL CORRESPONDENT Yoshi Terai
President, CEO
Asahi Intecc USA, Inc.
2500 Red Hill Avenue, Suite 210
Santa Ana, CA 92705
Tel: (949) 756-8252
FAX (949) 756-8165
e-mail: yoshi.terai@asahi-intecc.com

TRADE NAME: ASAHI CHIKAI 10 Neurovascular Guide Wire

COMMON NAME: Guide Wire

CLASSIFICATION NAME: Wire, Guide, Catheter

DEVICE CLASSIFICATION: Class 2 per 21 CFR §870.1330

PRODUCT CODE MOF - Catheter Guide Wire

PREDICATE DEVICE: 1. Asahi - ASAHI CHIKAI Neurovascular Guide Wire - 510(k) K110584
2. Micro Therapeutics, Inc. / EV3 - SilverSpeed Hydrophilic Guidewire - 510(k) K993257
3. Asahi - JoWire Neo's PTCA Guide Wire - 510(k) K022762
4. BSC/SciMed Life Systems, Inc. - Transend EX Platinum Guidewire -510(k) K971254
Additional referenced 510(k) cleared device:
5. Asahi - ASAHI SION PTCA Guide Wire - 510(k) K100578

DESCRIPTION OF THE DEVICE SUBJECT TO PREMARKET NOTIFICATION:

The ASAHI CHIKAI 10 Neurovascular Guide Wire is a steerable guide wire with a maximum diameter of 0.010 inches (0.26mm) and available in 200 cm and 300 cm lengths. The extension wire is connected to the end of the guide wire outside the body for 200 cm wire. The guide wire is constructed from a stainless steel core wire with platinum-nickel and stainless steel coils. The coil assembly consists of an inner coil and an outer coil, and the coil assembly is soldered to the core wire. The coil assembly construction is similar to the 510k cleared ASAHI CHIKAI Neurovascular Guide Wire with K110584.

The distal end of the guide wire has a radiopaque tip to achieve visibility, and is available in a straight configuration and can be made to bend easily with the vessel curve. A

510(k) SUMMARY

hydrophilic coating is applied to the distal portion of the guide wire. The proximal section of the guide wire for 300 cm wire is coated with PTFE.

INDICATION FOR USE:

ASAHI Neurovascular Guide Wire is intended to be used in the neuro vasculature to facilitate the placement and exchange of therapeutic devices such as cerebral catheters during intravascular therapy. This guide wire is intended for use only in the neuro vasculature.

TECHNICAL CHARACTERISTICS:

Comparisons of the ASAHI CHIKAI 10 Neurovascular Guide Wire and predicate devices show that the technological characteristics such as product performance, design and intended use are substantially equivalent to the current marketed predicate devices. The ASAHI CHIKAI 10 Neurovascular Guide Wire is similar in design - device dimensional specifications, and intended use, manufacturing process, operating principle, shelf life and sterilization process are the same and materials that have been used in other predicate devices in that its core wire, tip coils and solders remain the same.

PERFORMANCE DATA:

Enclosed within this submission is performance data that demonstrates that the ASAHI CHIKAI 10 Neurovascular Guide Wire meets all predetermined performance criteria. All components that come in direct contact with the patient have a long history of use in medical devices and are proven to be biocompatible for use in the vasculature. Furthermore, this submission contains reference to predicate ASAHI devices that use the same materials as used in the subject device.

In vitro bench testing, including tensile strength, torque strength, torqueability, tip flexibility, coating adherence, catheter compatibility, particulate testing and shelf life testing as listed below were conducted on the ASAHI CHIKAI 10 Neurovascular Guide Wire. This 510(k) notice includes mechanical and functional bench testing that demonstrates that the ASAHI CHIKAI 10 Neurovascular Guide Wire performs as intended.

The biocompatibility has been established by the successful use of the same materials and manufacturing process in currently 510(k) approved Asahi Guide Wire products.

Performance test/evaluation summary:

Device performance:

Tensile Strength

Turns to Failure (Torque Strength)

Torqueability (Torque Response)

Tip Flexibility

Coating Adhesion

Slipping Ability of Guide Wire with Microcatheter

Additional bench testing

Particulate testing

510(k) SUMMARY

Biocompatibility/evaluation:

Systemic Toxicity Study
In Vitro Hemolysis Study
Intracutaneous Study
Cytotoxicity Study
Sensitization Study
Pyrogen Study
Plasma Recalcification Time Coagulation Study
In Vivo Thromboresistance Study
C3a Complement Activation Study
SC5b-9 Complement Activation Study

SUMMARY/CONCLUSION:

The ASAHI CHIKAI 10 Neurovascular Guide Wire characteristics are substantially equivalent to the specified predicate device and other currently marketed devices for the same indication for use.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

Asahi Intecc Co., Ltd.
c/o Mr. Yoshi Terai
President, CEO
2500 Red Hill Ave., Suite 210
Santa Ana, CA 92705

DEC - 1 2011

Re: K112979

Trade/Device Name: ASAHI CHIKAI 10 Neurovascular Guide Wire
Regulation Number: 21 CFR 870.1330
Regulation Name: Catheter Guide Wire
Regulatory Class: Class II
Product Code: MOF
Dated: October 5, 2011
Received: October 12, 2011

Dear Mr. Terai:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucml15809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic, Neurological,
and Ear, Nose and Throat Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K112979

Device Name: ASAHI CHIKAI 10 Neurovascular Guide Wire

Indications for Use:

ASAHI Neurovascular Guide Wire is intended to be used in the neuro vasculature to facilitate the placement and exchange of therapeutic devices such as cerebral catheters during intravascular therapy. This guide wire is intended for use only in the neuro vasculature.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

JOE HUTTER

(Division Sign-Off)

Division of Ophthalmic, Neurological and Ear,
Nose and Throat Devices

Page _____ of _____

510(k) Number K112979